Here is a company that has completed several phase 2a tests on human patients with Alzheimer's disease. One phase 2b test with 400 AD patients started in February, 1999. All tests so far show that their drug, Neotrofin, is absorbed orally, biologically active within hours, and turns on the genes producing nerve growth factors. Basically, new nerve cells are produced and the memory process regenerated, without regard as to why the old ones failed. All tests thus far confirm same thing, improvement in memory and function. This is not just a slowing of the degenerative process as current drugs on the market seek to accomplish. Other drugs they have in the same family target dementia, spinal cord injury, stroke, and other central nervous system problems. A presentation to the 3rd Annual International Conference on Neurodegeneration is scheduled on July 27, 1999 to present an early evaluation of the drug, based on completed clinical trials. They are at least a year ahead of all other firms in this field.
I submit that the stock, now 15 3/4, and the warrants, now 6 1/4 are the buy of a lifetime. |
